Overview

A Study of Drug-drug Interaction Between Ritonavir and TMC435350 in Healthy Volunteers

Status:
Completed
Trial end date:
2008-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the drug-drug interaction between steady-state concentrations of CYP3A4 or ritonavir and TMC435350 after its first and the last dose of the multiple dosing regimen and to explore the short term safety and tolerability of multiple doses of 200 mg of TMC435350 administered alone and in combination with 100 mg of ritonavir.
Phase:
Phase 1
Details
Lead Sponsor:
Tibotec Pharmaceuticals, Ireland
Treatments:
Ritonavir
Simeprevir